Illicit Drug Use, Depression and Their Association with Highly Active Antiretroviral Therapy in HIV-positive Women

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2007 Feb 13

PMID 17291696

Citations 48

Authors

Judith A Cook

Dennis D Grey

Jane K Burke-Miller

Mardge H Cohen

David Vlahov

Farzana Kapadia

Tracey E Wilson

Robert Cook

Rebecca M Schwartz

Elizabeth T Golub

Kathryn Anastos

Claudia Ponath

Lakshmi Goparaju

Alexandra M Levine

Affiliations

Soon will be listed here.

Abstract

Background: We examined the interaction of illicit drug use and depressive symptoms, and how they affect the subsequent likelihood of highly active antiretroviral therapy (HAART) use among women with HIV/AIDS.

Methods: Subjects included 1710 HIV-positive women recruited from six sites in the U.S. including Brooklyn, Bronx, Chicago, Los Angeles, San Francisco/Bay Area, and Washington, DC. Cases of probable depression were identified using depressive symptom scores on the Center for Epidemiologic Studies Depression Scale. Crack, cocaine, heroin, and amphetamine use were self-reported at 6-month time intervals. We conducted multivariate random logistic regression analysis of data collected during 16 waves of semiannual interviews conducted from April 1996 through March 2004.

Results: We found an interaction effect between illicit drug use and depression that acted to suppress subsequent HAART use, controlling for virologic and immunologic indicators, socio-demographic variables, time, and study site.

Conclusions: This is the first study to document the interactive effects of drug use and depressive symptoms on reduced likelihood of HAART use in a national cohort of women. Since evidence-based behavioral health and antiretroviral therapies for each of these three conditions are now available, comprehensive HIV treatment is an achievable public health goal.

Citing Articles

Childhood trauma, substance use and depressive symptoms in people with HIV during COVID-19.

Singh N, Ntlantsana V, Tomita A, Paruk S S Afr J Psychiatr. 2024; 30:2220.

PMID: 39507827 PMC: 11538176. DOI: 10.4102/sajpsychiatry.v30i0.2220.

Use of machine learning approaches to predict transition of retention in care among people living with HIV in South Carolina: a real-world data study.

Cai R, Yang X, Ma Y, Zhang H, Olatosi B, Weissman S AIDS Care. 2024; 36(12):1745-1753.

PMID: 38833544 PMC: 11560699. DOI: 10.1080/09540121.2024.2361245.

Prevalence, correlates, and quality-of-life outcomes of major or persistent pain among women living with HIV in Metro Vancouver, Canada.

Ly S, Shannon K, Braschel M, Zhou H, Krusi A, Deering K Harm Reduct J. 2024; 21(1):10.

PMID: 38218886 PMC: 10788033. DOI: 10.1186/s12954-023-00859-x.

Common antiretroviral combinations are associated with somatic depressive symptoms in women with HIV.

Parra-Rodriguez L, OHalloran J, Wang Y, Jin W, Dastgheyb R, Spence A AIDS. 2023; 38(2):167-176.

PMID: 37773048 PMC: 11833910. DOI: 10.1097/QAD.0000000000003730.

Longitudinal determinants of anal intercourse among women with, and without HIV in the United States.

Owen B, Baggaley R, Maheu-Giroux M, Elmes J, Adimora A, Ramirez C BMC Womens Health. 2022; 22(1):291.

PMID: 35836248 PMC: 9284855. DOI: 10.1186/s12905-022-01849-0.

References

Moore J, Schuman P, Schoenbaum E, Boland B, Solomon L, Smith D . Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS. 1999; 13(17):2459-68. DOI: 10.1097/00002030-199912030-00018. View

Golub E, Astemborski J, Hoover D, Anthony J, Vlahov D, Strathdee S . Psychological distress and progression to AIDS in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2003; 32(4):429-34. DOI: 10.1097/00126334-200304010-00013. View

Sherbourne C, Hays R, Fleishman J, Vitiello B, Magruder K, Bing E . Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am J Psychiatry. 2000; 157(2):248-54. DOI: 10.1176/appi.ajp.157.2.248. View

Cruess D, Antoni M, Schneiderman N, Ironson G, McCabe P, Fernandez J . Cognitive-behavioral stress management increases free testosterone and decreases psychological distress in HIV-seropositive men. Health Psychol. 2000; 19(1):12-20. DOI: 10.1037//0278-6133.19.1.12. View

Chan K, Yip B, Wood E, Montaner J, OShaughnessy M, Hogg R . Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr. 2000; 23(4):295-301. DOI: 10.1097/00126334-200004010-00003. View

Sambamoorthi U, Walkup J, Olfson M, Crystal S . Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. J Gen Intern Med. 2000; 15(5):311-20. PMC: 1495453. DOI: 10.1046/j.1525-1497.2000.06219.x. View

Bogart L, Kelly J, Catz S, Sosman J . Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000; 23(5):396-404. DOI: 10.1097/00126334-200004150-00006. View

Anderson K, Mitchell J . Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med. 2000; 160(20):3114-20. DOI: 10.1001/archinte.160.20.3114. View

Diala C, Muntaner C, Walrath C, Nickerson K, LaVeist T, Leaf P . Racial differences in attitudes toward professional mental health care and in the use of services. Am J Orthopsychiatry. 2000; 70(4):455-64. DOI: 10.1037/h0087736. View

10.

Cunningham W, Markson L, Andersen R, Crystal S, Fleishman J, Golin C . Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000; 25(2):115-23. DOI: 10.1097/00042560-200010010-00005. View

11.

Ickovics J, Hamburger M, Vlahov D, Schoenbaum E, Schuman P, Boland R . Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001; 285(11):1466-74. DOI: 10.1001/jama.285.11.1466. View

12.

Diala C, Muntaner C, Walrath C, Nickerson K, LaVeist T, Leaf P . Racial/ethnic differences in attitudes toward seeking professional mental health services. Am J Public Health. 2001; 91(5):805-7. PMC: 1446685. DOI: 10.2105/ajph.91.5.805. View

13.

Richardson J, Barkan S, Cohen M, Back S, Fitzgerald G, Feldman J . Experience and covariates of depressive symptoms among a cohort of HIV infected women. Soc Work Health Care. 2001; 32(4):93-111. DOI: 10.1300/J010v32n04_05. View

14.

Celentano D, Galai N, Sethi A, Shah N, Strathdee S, Vlahov D . Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001; 15(13):1707-15. DOI: 10.1097/00002030-200109070-00015. View

15.

Turner B, Fleishman J, Wenger N, London A, Burnam M, Shapiro M . Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001; 16(9):625-33. PMC: 1495260. DOI: 10.1046/j.1525-1497.2001.016009625.x. View

16.

Cook J, Cohen M, Grey D, Kirstein L, Burke J, Anastos K . Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health. 2002; 92(1):82-7. PMC: 1447394. DOI: 10.2105/ajph.92.1.82. View

17.

DiIorio C, Hartwell T, Hansen N . Childhood sexual abuse and risk behaviors among men at high risk for HIV infection. Am J Public Health. 2002; 92(2):214-9. PMC: 1447045. DOI: 10.2105/ajph.92.2.214. View

18.

Cooper E, Charurat M, Mofenson L, Hanson I, Pitt J, Diaz C . Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002; 29(5):484-94. DOI: 10.1097/00126334-200204150-00009. View

19.

Morrison M, Petitto J, Ten Have T, Gettes D, Chiappini M, Weber A . Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry. 2002; 159(5):789-96. DOI: 10.1176/appi.ajp.159.5.789. View

20.

Cohen M, French A, Benning L, Kovacs A, Anastos K, Young M . Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002; 113(2):91-8. PMC: 3126666. DOI: 10.1016/s0002-9343(02)01169-5. View